Washington is currently home to 1729 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Brain and Behavior Influences on Obesity Development From Infancy Through Childhood
NCT06861868
Recruiting
The investigators project, RESONATE, aims to investigate why some children develop obesity. To do this it uses data on eating and eating-related behaviors, genetic and environmental factors, and brain structure and function. This data is collected in a sub-sample of RESONANCE, a large study of families of children from infancy through childhood. The results will lay foundations for the development of early interventions to prevent or treat obesity.
Gender:
ALL
Ages:
Between 7 years and 12 years
Trial Updated:
03/05/2025
Locations: University of Washington, Seattle, Washington
Conditions: Obesity and Overweight
Register for Updates
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193
Recruiting
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Register for Updates
IV Gallium Study for Patients with Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Recruiting
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Nontuberculous Mycobacterium Infection
Register for Updates
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Neurocrine Clinical Site, Everett, Washington
Conditions: Major Depressive Disorder
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Washington /ID# 243172, Seattle, Washington
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: MultiCare Institute - Mary Bridge Children's Neurology, Tacoma, Washington
Conditions: Partial Epilepsy
Register for Updates
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
NCT06357832
Recruiting
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatmen... Read More
Gender:
ALL
Ages:
Between 22 years and 68 years
Trial Updated:
03/02/2025
Locations: ClearPath Psychiatry, Seattle, Washington
Conditions: Major Depressive Disorder
Register for Updates
Hand and Arm Motor Recovery Via Non-invasive Electrical Spinal Cord Stimulation After Stroke
NCT05591196
Recruiting
The recovery from a stroke is often incomplete. It is the leading cause of acquired permanent disability in the adult population. Persistent functional loss of the hand and arm contributes significantly to disability. However, the current standard of care to treat hand and arm movements are inadequate. There is an urgent need for innovative and effective therapies for recovery of the upper limb after stroke. Growing evidence shows that electrical spinal cord stimulation, combined with activity-... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
02/28/2025
Locations: University of Washington, Seattle, Washington
Conditions: Stroke, Ischemic, Chronic Stroke
Register for Updates
Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
NCT05267951
Recruiting
The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
02/28/2025
Locations: University of Washington, Seattle, Washington
Conditions: Spinal Cord Injuries
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Seattle, Washington
Conditions: Neoplasms
Register for Updates
Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Washington, Seattle, Washington
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
NCT06323837
Recruiting
This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA use and related health-impairing behaviors. MZP has already successfully been used in the treatment of methamphetamine (detailed further below and in the Appendices). The investigators hypothesize tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Spokane Treatment Center, Spokane, Washington
Conditions: Stimulant Use Disorder
Register for Updates